Neurological disorder biotech Intra-Cellular Therapies files for a $115 million IPO

By
A A A

Intra-Cellular Therapies, a clinical-stage biotech developing treatments for neurological disorders, filed on Friday with the SEC to raise up to $115 million in an initial public offering. The New York, NY-based company, which was founded in 2012, plans to list on the NASDAQ under the symbol ITCI. It is currently traded on the OTC market under the same ticker. Leerink Partners and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: ITCI

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

270,887,127
    $93.89 unch
225,243,115
  • $40.93 ▼ 2.74%
135,900,109
  • $47.52 ▲ 1.80%
89,467,924
  • $5.35 ▼ 1.11%
85,105,358
  • $16.95 ▼ 0.53%
80,748,539
  • $39.80 ▼ 4.21%
68,491,586
  • $3.57 ▼ 1.79%
62,097,356
  • $100.96 ▼ 0.82%
As of 9/19/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com